The
Philippine government under the Duterte administration is in close contact with
its counterparts from Japan for the planned clinical trials of the Avigan drug
for the novel coronavirus disease 2019 (COVID-19) patients in the country.
Avigan, a
Japanese anti-influenza drug otherwise known as Faviravir, has been touted as a
promising treatment for Covid-19.
"Nagkaroon po
tayo ng kasunduan sa government of Japan kung saan
mayroon po tayong pagkakasunduan, kung magiging clear po ang ating arrangement, ito pong isang
gamot ay Avigan pero nasa initial stages of coordination pa lang tayo (We had an agreement with the government of Japan, once
the arrangement has been clear, the medicine would be Avigan. At present we are
in the initial stages of coordination)," DOH Undersecretary Maria Rosario
Vergeire said said during the
Laging Handa briefing.
(photo credit to owner) |
Aside from this medicine, Vergeire
said the Philippines is exploring other ways to manage Covid-19 cases.
"Sa UP (PGH), nag-umpisa
na po sila ng kanilang convalescent plasma therapy na clinical
trial, naumpisan na sa ibang pasyente at mayroon na silang nire-report na
maganda pero hindi pa po 'yan enough evidence na kumpleto para masabi
na ito talaga ay epektibo (At UP, they already started their convalescent
plasma therapy on clinical trial, they've been reporting good results but that
is not enough evidence to say this is really effective)," she said.
The University of the
Philippines-Philippine General Hospital (UP-PGH) is the only hospital in the
country with approved protocol to conduct such procedure, said Usec. Vergeire.
What can you say about this?
Share us your thoughts by simply leaving on the
comment section below. For more news updates, feel free to visit our site
often.
Stay
updated with today's relevant news and trends by hitting the LIKE button.
Thanks
for dropping by and reading this post.
Report from PNA
Disclaimer:
Contributed articles does not reflect the view of THE PH CHRONICLES. This website cannot guarantee
the legitimacy of some of the information contributed to us. You may do additional
research if you find some information doubtful. No part of this article
maybe reproduced without permission from this website.
0 Comments